Keros' lead product candidate is rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, while its most advanced product candidate, elritercept, is being developed for cytopenias in myelodysplastic syndrome and myelofibrosis patients. The company posted a net loss of $7.3 million in Q3 2025 versus $53.0 million in Q3 2024, driven by revenue recognized under its license agreement with Takeda.
Cyborg Score Rationale
Keros has a Buy consensus rating from 7 analysts as of February 17, 2026. The company plans to initiate a Phase 2 clinical trial of KER-065 in DMD patients in Q1 2026, following positive Phase 1 results. The company has improving financial performance and a strong, low-leverage balance sheet supported by positive corporate actions.
Top Insights
Company plans Phase 2 trial of lead asset KER-065 in DMD patients in Q1 2026 with orphan drug status designation
Completed $375 million capital return program with buyback of 35.91% of outstanding shares by November 2025
Recently appointed Charles Newton, a veteran healthcare investment banker with healthcare finance expertise, to Board of Directors effective March 9, 2026
Discontinued cibotercept PAH program in August 2025 to redirect resources toward KER-065, the company's more promising lead asset